Movement Alert｜Johnson & Johnson Rises 3.1% in Regular Trading, Tecvayli Combination Therapy Receives EMA Committee Recommendation for Expanded Indication

Market Focus06-26

On June 26, Johnson & Johnson rose 3.1% in regular trading, trading at $253.16/share, with turnover of $697 million.

On the news front, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended expanding Tecvayli's approval in combination with daratumumab for adult patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. The recommendation was based on Phase 3 MajesTEC-3 study data showing an 83.4% reduction in the risk of disease progression or death in patients treated with teclistamab plus daratumumab subcutaneous compared with standard of care.

Additionally, Guggenheim raised its price target on Johnson & Johnson to $270 from $266, maintaining a Buy rating. The stock's average analyst rating is overweight with a mean price target of $262.10.

Within the Pharmacy sector, the overall tone was positive. Among peers, Eli Lilly rose 5.77%, Merck rose 2.34%, Pfizer rose 2.34%, Novo-Nordisk rose 1.32%, and Novartis rose 0.48%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1121043597?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-26 22:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121043597","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Johnson & Johnson Rises 3.1% in Regular Trading, Tecvayli Combination Therapy Receives EMA Committee Recommendation for Expanded Indication","media":"Market Focus","content":"<p><p>On June 26, Johnson & Johnson rose 3.1% in regular trading, trading at $253.16/share, with turnover of $697 million.</p><p>On the news front, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended expanding Tecvayli's approval in combination with daratumumab for adult patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. The recommendation was based on Phase 3 MajesTEC-3 study data showing an 83.4% reduction in the risk of disease progression or death in patients treated with teclistamab plus daratumumab subcutaneous compared with standard of care.</p><p>Additionally, Guggenheim raised its price target on Johnson & Johnson to $270 from $266, maintaining a Buy rating. The stock's average analyst rating is overweight with a mean price target of $262.10.</p><p>Within the Pharmacy sector, the overall tone was positive. Among peers, Eli Lilly rose 5.77%, Merck rose 2.34%, Pfizer rose 2.34%, Novo-Nordisk rose 1.32%, and Novartis rose 0.48%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Johnson & Johnson Rises 3.1% in Regular Trading, Tecvayli Combination Therapy Receives EMA Committee Recommendation for Expanded Indication</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Johnson & Johnson Rises 3.1% in Regular Trading, Tecvayli Combination Therapy Receives EMA Committee Recommendation for Expanded Indication\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-26 22:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 26, Johnson & Johnson rose 3.1% in regular trading, trading at $253.16/share, with turnover of $697 million.</p><p>On the news front, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended expanding Tecvayli's approval in combination with daratumumab for adult patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. The recommendation was based on Phase 3 MajesTEC-3 study data showing an 83.4% reduction in the risk of disease progression or death in patients treated with teclistamab plus daratumumab subcutaneous compared with standard of care.</p><p>Additionally, Guggenheim raised its price target on Johnson & Johnson to $270 from $266, maintaining a Buy rating. The stock's average analyst rating is overweight with a mean price target of $262.10.</p><p>Within the Pharmacy sector, the overall tone was positive. Among peers, Eli Lilly rose 5.77%, Merck rose 2.34%, Pfizer rose 2.34%, Novo-Nordisk rose 1.32%, and Novartis rose 0.48%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JNJ","symbol_name":"强生","start_time":0,"source_url":"","article_id":"1121043597","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121043597","pubTimestamp":1782484174,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 26, Johnson & Johnson rose 3.1% in regular trading, trading at $253.16/share, with turnover of $697 million.On the news front, the European Medicines Agency's Committee for Medicinal Products...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"JNJ":"强生"},"translate_title":"动向预警|强生常规交易涨3.1%Tecvayli组合疗法获EMA委员会推荐扩大适应症","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":1},"content_text":"On June 26, Johnson & Johnson rose 3.1% in regular trading, trading at $253.16/share, with turnover of $697 million.On the news front, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended expanding Tecvayli's approval in combination with daratumumab for adult patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. The recommendation was based on Phase 3 MajesTEC-3 study data showing an 83.4% reduction in the risk of disease progression or death in patients treated with teclistamab plus daratumumab subcutaneous compared with standard of care.Additionally, Guggenheim raised its price target on Johnson & Johnson to $270 from $266, maintaining a Buy rating. The stock's average analyst rating is overweight with a mean price target of $262.10.Within the Pharmacy sector, the overall tone was positive. Among peers, Eli Lilly rose 5.77%, Merck rose 2.34%, Pfizer rose 2.34%, Novo-Nordisk rose 1.32%, and Novartis rose 0.48%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1121043597","isCrawlerRequest":true}